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Pseudotype viruses: applications and troubleshooting, Cineworld, The O2, London, 
UK, 2 October 2013 
Pseudotype viruses: applications and troubleshooting’ (EuroSciCon 2013), a 1-day 
conference held at Cineworld: The O2 (London, UK) on 2 October 2013, focused on 
the technique of pseudotyping enveloped viruses (for a review of the technique, 
see [1]). The talks and posters covered the challenges and successes of pseudotyping 
viruses from a broad range of families (Retroviridae, Flaviviridae, Orthomyxoviridae, 
Bunyaviridae and Rhabdoviridae) for a variety of applications. The conference was 
chaired by Nigel Temperton, University of Kent (UK), who placed a strong emphasis 
on using this event to explore the technical challenges of pseudotyping viruses, 
especially during the poster and afternoon question and answer sessions.
Serological diagnosis of virus infection
The first talk, by Janet Daly, University of Nottingham (UK), provided an overview of current meth-
ods for serological diagnosis of viral infections. The plaque reduction neutralization test (PRNT) 
is typically used for viruses that cause transient or low-level viremia, which hampers diagnosis by 
molecular techniques. PRNT detects the presence of ‘virus-neutralizing’ antibodies (vNAbs or 
NAbs) in patient sera which, when mixed with infectious virus, bind the virus and prevent entry 
into cells. PRNT is considered the ‘gold standard’ diagnostic for a number of viruses, despite hav-
ing significant limitations: it is low throughput, time consuming (virus-induced cytopathic effect 
can take 3–5 days to develop) and requires the use of infectious virus, which often requires a high 
level of containment. Pseudotype viruses (PVs) can be used as a surrogate for the wild-type virus 
used in PRNT as they are not infectious but express the targets of neutralizing antibodies. They 
are ideally suited to high-throughput assessment of sero-prevalence and -conversion using smaller 
sample volumes than conventional techniques.
The varied application of PVs for controlling influenza
Two talks from Simon Scott and Nigel Temperton, Viral Pseudotype Unit [2], University of Kent, 
described the versatility of influenza pseudotypes. In addition to the basic components, production of 
influenza PVs also requires the exogenous supply of a trypsin-like protease and recombinant neura-
minidase for maturation of the hemagglutinin and release of the PVs from the cell surface, respec-
tively. Simon Scott’s group have developed a PV neutralization assay (PVNA) for equine influenza
virus to improve the assessment of vaccine efficacy. In contrast to the traditional single radial 
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hemolysis assay, the PVNA is high throughput 
and quantification is digital, not manual. Nigel 
Temperton’s group have focused on the appli-
cation of PV assays for pandemic preparedness 
by producing a comprehensive portfolio of PVs 
for different influenza virus hemagglutinin sub-
types. By using commercial gene synthesis ser-
vices, the group is able to analyze the potential 
threat of newly emerging viruses by generating 
PVs without needing to obtain live virus. These 
PVs can be used to determine whether current 
vaccines will provide protection against new 
strains and, by altering the target cell used in 
the PVNA, their zoonotic potential. The Viral 
Pseudotype Unit is also developing methods for 
freeze-drying PVs to facilitate distribution of 
PVs to other laboratories and multiplexing to 
improve sero-surveillance.
PVNA in the absence of an effective 
diagnostic
Molecular methods have surpassed serological 
techniques for clinical diagnosis of many dis-
eases, particularly acute infections. However, 
Edward Wright, University of Westminster 
(London, UK), described the case of Serengeti 
National Park (Tanzania), where the highly 
unreliable power supply prevents detection of 
rabies virus infection by standard molecular 
methods. To overcome this challenge, Wright 
and colleagues have produced PVs of rabies 
challenge virus standard II on a lentivirus back-
bone [3]. Using a β-galactosidase reporter gene, 
for which low-cost colorimetric substrates are 
available, they were able to generate a PVNA 
highly suited for use in laboratories with limited 
resources and with comparable sensitivity with 
PVs using luciferase or GFP reporter genes. Later 
in the day, Brian Willett, University of Glasgow 
Centre for Virus Research (Scotland), high-
lighted how readily transferable the rabies PV 
system was; his group used plasmids provided 
by Wright to detect antibodies in lions.
David Griffiths, Moredun Research Institute, 
introduced Jaagsiekte sheep retrovirus (JSRV), 
the causative agent of ovine pulmonary adeno-
carcinoma. Current diagnosis of JSRV infection 
relies upon clinical presentation. The apparent 
lack of an acquired immune response to the 
virus has hampered development of serological 
assays and vaccines. However, using PVs with 
target cells that stably express the JSRV host cell 
receptor ovine hyaluronidase-2, Griffiths and 
colleagues have provided the first evidence that 
sheep naturally infected with JSRV are capable 
of producing antibodies to the virus. Their work 
is now focused on developing the PV system as 
a diagnostic.
Pseudotyping as a research tool
Katherine Sutherland, Colindale Public Health 
England (London, UK), described a fascinat-
ing use of HIV particles pseudotyped with the 
VSV-g to analyze resistance to antiviral com-
pounds. Standard screening processes for pro-
tease inhibitors focus on the development of 
mutations in the protease itself. However, by 
cloning the gag/pol gene sequences from patients 
into the HIV PV backbone, Sutherland and col-
leagues are uniquely able to analyze the effect 
of cleavage site mutations within the Gag/Pol 
polyprotein. Interestingly, they found that cleav-
age site escape mutants are largely responsible 
for the development of resistance to protease 
inhibitors [4].
Brian Willett and his colleagues are using 
PVs to study a range of viruses for a variety of 
applications. We were informed that pseudo-
typing can be relatively straightforward when 
the virus of interest is closely related to the 
backbone virus; for example, feline immunode-
ficiency virus (FIV) envelope (Env) on a HIV 
backbone, whereas pseudotyping Envs from 
unrelated viruses can be more problematic. FIV 
alters its tropism throughout infection, going 
from an ‘early infection’ form, characterized by 
a dependence on the CRD2 of the FIV entry 
receptor CD134, to a CRD2-independent ‘late 
infection’ form [5]. This shift in tropism can be 
monitored using the PV system and target cells 
differentially expressing the wild-type or mutant 
CD134.
Pseudotyping Rift Valley fever virus (RVFV) 
was initially unsuccessful until high levels of 
expression of the RVFV Env proteins Gn and Gc 
were achieved; even then PV titers were relatively 
low. It is thought this is because RVFV buds into 
the Golgi while the HIV particles, which form 
the backbone of the PVs, assemble at the plasma 
membrane. Therefore, it was only when levels of 
RVFV glycoprotein saturated the normal route 
of maturation that sufficient amounts reached 
sites of assembly, enabling PV formation.
Canine distemper virus (CDV) brought a 
different challenge as high levels of cytopathic 
effect in PV producer cells caused by the CDV 
glycoproteins prevented accumulation of high 
titers of infectious PVs. But, by drawing from 
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previous studies on measles virus [6], a combina-
tion of truncations of the CDV glycoproteins H 
and F was found that produced usable titers of 
infectious PVs.
HCV is a highly variable virus, with much 
of the diversity within the Env glycoprotein 
genes, E1 and E2. Alex Tarr, University of 
Nottingham, and colleagues have isolated, 
cloned and sequenced the Env genes from 
over 600 patients and analyzed their infec-
tivity using a luciferase-based PV system [7]. 
Approximately 25% of the isolates produced 
infectious PVs and a selection of the most infec-
tious PVs was used to screen patient samples to 
identify broadly neutralizing sera. The patient 
sera tested fell into three distinct groups: those 
that broadly neutralized; those that neutralized 
some isolates but enhanced the infectivity of 
others and those that were broadly enhancing 
(the majority). vNAbs isolated from the broadly 
neutralizing sera mapped to the binding site of 
one of the HCV receptors, CD81. The group 
is investigating the use of a pool of vAbs as a 
therapy for prevention of rapid HCV infection 
of transplanted livers.
Ask an expert
In the afternoon there was a vibrant question 
and answer session on the production and analy-
sis of PVs and the reagents used. Notably, the 
panel recommended the use of a visual output 
reporter, such as GFP or β-galactosidase in 
conjunction with X-gal, rather than luciferase, 
to enable discrimination between wide-spread 
low-level reporter expression and isolated cells, 
with high levels of reporter expression to facili-
tate optimization of the PV production protocol. 
Several speakers described the application of a 
NanoSight (Amesbury, UK) nanoparticle ana-
lyzer to quantify the size and number of nano-
particles per preparation. Comparison of wild-
type and PV preparations using this technology 
could be useful for evaluating the relative effi-
ciency of particle production. There was also a 
consensus of opinion that using secreted alkaline 
phosphatase as a reporter in combination with 
a chemiluminescent substrate would offer the 
greatest benefit in terms of cost, throughput and 
sensitivity.
Conclusion
The fascinating array of talks from experienced 
researchers working on a wide range of viruses 
provided attendees with an excellent overview 
of the varied applications and challenges of 
pseudo typing. Unlike other virus-specific con-
ferences, where competition between groups can 
limit frankness, this event was buzzing with a 
strong sense of openness, with participants will-
ing to exchange both experimental details and 
reagents. Such was the success of the event that 
a further meeting in a year’s time is already 
planned.
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